On Invalid Date, Eli Lilly & Co (NYSE: LLY) reported Q2 2023 earnings per share (EPS) of $1.96, up 84.91% year over year. Total Eli Lilly & Co earnings for the quarter were $1.76 billion. In the same quarter last year, Eli Lilly & Co's earnings per share (EPS) was $1.06.
As of Q3 2023, Eli Lilly & Co's earnings has grown 14.63% year over year. This is 21.81 percentage points higher than the US Drug Manufacturers - General industry earnings growth rate of -7.18%. Eli Lilly & Co's earnings in the past year totalled $6.50 billion.
What is LLY's earnings date?
Eli Lilly & Co's earnings date is Invalid Date. Add LLY to your watchlist to be reminded of LLY's next earnings announcement.
What was LLY's revenue last quarter?
On Invalid Date, Eli Lilly & Co (NYSE: LLY) reported Q2 2023 revenue of $8.31 billion up 28.11% year over year. In the same quarter last year, Eli Lilly & Co's revenue was $6.49 billion.
What was LLY's revenue growth in the past year?
As of Q3 2023, Eli Lilly & Co's revenue has grown 1.53% year over year. This is 1.64 percentage points higher than the US Drug Manufacturers - General industry revenue growth rate of -0.11%. Eli Lilly & Co's revenue in the past year totalled $29.52 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.